2024 ASH Highlights


Review presentations and information shared by Dana-Farber physician-scientists at the 67th American Society of Hematology Annual Meeting & Exposition in San Diego on Dec. 1-10th, 2024.

Colleen Kelly, MD discusses findings on RISE Video

Colleen Kelly, MD discusses findings on RISE

At #ASH24, researcher, Colleen Kelly MD, presented findings on RISE, a Dana-Farber led program aiding low-income families of kids with cancer. Results show promise.
Shai Shimony, MD, MPH reviews Phase 3 acute myeloid leukemia trial Video

Shai Shimony, MD, MPH reviews Phase 3 acute myeloid leukemia trial

Findings from a Phase 3 acute myeloid leukemia trial presented at #ASH24 show CPX-351 improves survival for AML-MR patients. Lead authors Shai Shimony, MD, MPH, and H. Moses Murdoch, MD, of Dana-Farber Cancer Institute, explain more in this video.
Shai Shimony, MD

Shai Shimony, MD

Medical Oncology
Jennifer Brown, MD, PhD reviews Phase 2 Amplify trial Video

Jennifer Brown, MD, PhD reviews Phase 2 Amplify trial

Dana-Farber Cancer Institute's Jennifer Brown, MD, PhD, shared results at #ASH24 from the Phase 3 AMPLIFY trial: novel oral regimens show promise for CLL with durable, deep responses.
Jennifer R. Brown, MD, PhD

Jennifer R. Brown, MD, PhD

Medical Oncology
Katie Maurer, MD, PhD discusses HSCT treatment Video

Katie Maurer, MD, PhD discusses HSCT treatment

Katie Maurer, MD, PhD, from Dana-Farber Cancer Institute, shared #ASH24 findings suggesting that diverse bone marrow cell composition may predict treatment response in the content of AML patients undergoing HSCT.
Katie Maurer, MD

Katie Maurer, MD

Medical Oncology
Matthew Davids, MD, MMSc discusses time-limited AVO triplet therapy Video

Matthew Davids, MD, MMSc discusses time-limited AVO triplet therapy

In a new study published in the Journal of Clinical Oncology and presented at #ASH24, Matthew Davids, MD, MMSC, of Dana-Farber Cancer Institute, shared promising findings: a time-limited AVO triplet therapy offers durable remission for high-risk CLL patients.
Matthew Davids, MD, MMSc

Matthew Davids, MD, MMSc

Director, Clinical Research, Division of Lymphoma Physician
Jacqueline Garcia, MD on oral maintenance therapy in AML/MDS patients Video

Jacqueline Garcia, MD on oral maintenance therapy in AML/MDS patients

Jacqueline Garcia, MD, of Dana-Farber Cancer Institute presented at #ASH24 data suggesting oral maintenance therapy with venetoclax and decitabine/cedazuridine after HCT is safe, feasible, and may reduce relapse rates in high-risk AML/MDS patients.
Jacqueline Garcia, MD

Jacqueline Garcia, MD

Medical Oncology
Daniel DeAngelo, MD, PhD on a novel systemic mastocytosis (SM) drug Video

Daniel DeAngelo, MD, PhD on a novel systemic mastocytosis (SM) drug

Daniel DeAngelo, MD, PhD, of Dana-Farber Cancer Institute, presented findings at #ASH24 on two abstracts regarding a novel systemic mastocytosis (SM) drug with high response rates & a tool that identifies SM subtypes with 90% accuracy.
Daniel DeAngelo, MD, PhD

Daniel DeAngelo, MD, PhD

Chief, Division of Leukemia
Institute Physician
Professor of Medicine, Harvard Medical School
Ann Lacasce, MD, MMSc discusses treatment in early stage high-risk cHL patients Video

Ann Lacasce, MD, MMSc discusses treatment in early stage high-risk cHL patients

Ann Lacasce MD, MMSc, of Dana-Farber Cancer Institute presented findings at #ASH24 suggesting treatment with brentuximab vedotin and nivolumab can reduce toxicities and may decrease the need for radiation in early stage high-risk cHL patients.
Ann LaCasce, MD, MMSc

Ann LaCasce, MD, MMSc

Medical Oncology

Resources 

 

News Releases

 

Subscribe

 

Follow us on social media